Weight Loss News and Research

Latest Weight Loss News and Research

iVillage launches new Health site to help women manage their health needs online

iVillage today announced the launch of its new Health site (www.ivillage.com/Health), the first women's destination on the Web that combines medical expertise and original health content with community conversations and interactive tools, to help women manage their health needs online.

18 Mar 2010

Genes linked to ulcerative colitis identified

A study of the human genome led by Cedars-Sinai researchers has now identified genes linked to ulcerative colitis, offering clues as to what causes the condition and potential avenues for new therapies to treat the disease.

18 Mar 2010

Low-impact, weight-bearing exercise does not affect bone density during weight loss

While there are many benefits of losing weight, weight reduction also might negatively affect bones in the body. During weight loss, bones are being remodeled - breaking down old bone and forming new bone - at an accelerated rate.

17 Mar 2010

Anti-obesity drugs fail to tackle wider issues of obesity

Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.

17 Mar 2010

Adam 3XL addresses young people with weight problem

Adam 3XL (published by Trafford) by Dr. Martin Noelke is a novel about basketball, love, friendship ... and some nutritional guidelines for weight reduction in the long run. It's the story of a one-time high school basketball all-star who stops exercising and packs on the pounds after losing both of his parents. Dr. Noelke infuses his expertise as a general practitioner and nutrition specialist into the story to send a message to today's youth about health.

16 Mar 2010

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

16 Mar 2010

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Treating non-osteoporotic compression fractures in patients with multiple myeloma, a blood cancer, shows that the use of vertebroplasty-a minimally invasive treatment performed by interventional radiologists using imaging guidance that stabilizes collapsed vertebrae with the injection of medical-grade bone cement into the spine-results in a reduction of pain, medication usage and disability, according to researchers in the largest study of its kind at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

16 Mar 2010

Healthways, Blue Zones establish Healthways-Blue Zones Vitality Quest to improve community well-being

Today, Healthways, Inc. and Blue Zones, LLC, announced the establishment of Healthways-Blue Zones Vitality QuestSM, an exclusive, strategic relationship to create, support and sustain a national movement to improve community health and well-being, initially for cities in the U.S.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.

15 Mar 2010

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010

Collaborative center established to reduce obesity-related deaths in African-American and Latino communities

A $6 million grant from the National Heart, Lung and Blood Institute (NHLBI) has funded the creation of ORBIT: Obesity Related Behavioral Intervention Trials to focus on reducing obesity and obesity-related deaths in New York City's African-American and Latino communities.

11 Mar 2010

Patients who undergo gastric bypass surgery increase their risk of developing kidney stones

Patients who undergo gastric bypass surgery experience changes in their urine composition that increase their risk of developing kidney stones, research from UT Southwestern Medical Center investigators suggests.

10 Mar 2010

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Patients with irritable bowel syndrome are at no greater risk of having polyps, colon cancer or inflammatory bowel diseases than healthy people undergoing colonoscopies, according to new research published in the American Journal of Gastroenterology.

10 Mar 2010

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the three months and year ended December 31, 2009.

9 Mar 2010

Taxing less healthful foods may steer adults toward healthier diets

Adults tend to eat less pizza and drink less soda as the price of these items increases, and their body weight and overall calorie intake also appear to decrease, according to a report in the March 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Mar 2010

VIVUS granted three additional patents for Qnexa

VIVUS, Inc. today announced the issuance of three additional patents by the U.S. Patent and Trademark Office (USPTO) covering Qnexa, an investigational new drug candidate for the treatment of obesity. The three new patents are the second, third, and fourth patents to be granted in a series of patent applications VIVUS has filed that are directed to the Qnexa product and methods of using Qnexa in various therapeutic applications.

8 Mar 2010

Pediatrics researchers identify major gene location responsible for EoE

Pediatrics researchers have identified the first major gene location responsible for a severe, often painful type of food allergy called eosinophilic esophagitis (EoE). In this disease, which may cause weight loss, vomiting, heartburn and swallowing difficulties, a patient may be unable to eat a wide variety of foods.

7 Mar 2010

Weight Loss News and Research

Latest Weight Loss News and Research

iVillage launches new Health site to help women manage their health needs online

Genes linked to ulcerative colitis identified

Low-impact, weight-bearing exercise does not affect bone density during weight loss

Anti-obesity drugs fail to tackle wider issues of obesity

Adam 3XL addresses young people with weight problem

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

Vertebroplasty helps patients become better equipped to continue with treatment for multiple myeloma

Healthways, Blue Zones establish Healthways-Blue Zones Vitality Quest to improve community well-being

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

NDA for BYDUREON: FDA issues complete response letter

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Arena Pharmaceuticals reports lower net loss allocable to common stockholders in fourth-quarter 2009

New MMMCC center improves patients’ access to medical marijuana

Collaborative center established to reduce obesity-related deaths in African-American and Latino communities

Patients who undergo gastric bypass surgery increase their risk of developing kidney stones

IBS patients are at no greater risk of having polyps, colon cancer than healthy people undergoing colonoscopies

Orexigen Therapeutics reports net loss of $15.0M for three months ended December 31, 2009

Taxing less healthful foods may steer adults toward healthier diets

VIVUS granted three additional patents for Qnexa

Pediatrics researchers identify major gene location responsible for EoE

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Weight Loss News and Research

Latest Weight Loss News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in